# Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures

> **NCT06534502** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Azurity Pharmaceuticals** · enrollment: 40 (estimated)

## Conditions studied

- Seizures
- Seizures, Focal
- Seizure, Partial Onset
- Seizure Disorder, Partial
- Seizure, Partial
- Epilepsies, Partial
- Epilepsy

## Interventions

- **DRUG:** Zonisamide Oral Product

## Key facts

- **NCT ID:** NCT06534502
- **Lead sponsor:** Azurity Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2027-09
- **Final completion:** 2027-09
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06534502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06534502, "Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06534502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*